ArticleAnnals of hematology2022

Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience.

Emiliano Barbieri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.